1289 related articles for article (PubMed ID: 28036267)
41. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
[TBL] [Abstract][Full Text] [Related]
42. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
43. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
44. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3.
Bai X; Han G; Liu Y; Jiang H; He Q
Biomed Pharmacother; 2018 Jul; 103():1482-1489. PubMed ID: 29864933
[TBL] [Abstract][Full Text] [Related]
45. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor.
Kim HY; Ha Thi HT; Hong S
Cancer Lett; 2018 Feb; 415():30-39. PubMed ID: 29217458
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
47. Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3.
Toda H; Kurozumi S; Kijima Y; Idichi T; Shinden Y; Yamada Y; Arai T; Maemura K; Fujii T; Horiguchi J; Natsugoe S; Seki N
J Hum Genet; 2018 Dec; 63(12):1197-1210. PubMed ID: 30228364
[TBL] [Abstract][Full Text] [Related]
48. Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.
Shahbazi R; Asik E; Kahraman N; Turk M; Ozpolat B; Ulubayram K
Nanomedicine (Lond); 2017 Aug; 12(16):1961-1973. PubMed ID: 28745127
[TBL] [Abstract][Full Text] [Related]
49. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.
Adams BD; Wali VB; Cheng CJ; Inukai S; Booth CJ; Agarwal S; Rimm DL; Győrffy B; Santarpia L; Pusztai L; Saltzman WM; Slack FJ
Cancer Res; 2016 Feb; 76(4):927-39. PubMed ID: 26676753
[TBL] [Abstract][Full Text] [Related]
50. MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells.
Chu J; Li Y; Fan X; Ma J; Li J; Lu G; Zhang Y; Huang Y; Li W; Huang X; Fu Z; Yin Y; Yuan H
Cell Physiol Biochem; 2018; 48(2):593-604. PubMed ID: 30021199
[TBL] [Abstract][Full Text] [Related]
51. miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer.
Son D; Kim Y; Lim S; Kang HG; Kim DH; Park JW; Cheong W; Kong HK; Han W; Park WY; Chun KH; Park JH
Cancer Lett; 2019 Jul; 454():224-233. PubMed ID: 31004703
[TBL] [Abstract][Full Text] [Related]
52. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
53. EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer.
Wu Q; Chen Z; Zhang G; Zhou W; Peng Y; Liu R; Chen C; Feng J
Acta Biochim Biophys Sin (Shanghai); 2018 Jul; 50(7):693-700. PubMed ID: 29790898
[TBL] [Abstract][Full Text] [Related]
54. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
55. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
Wang S; Zhang J; Wang Y; Chen M
Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968
[TBL] [Abstract][Full Text] [Related]
56. DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC.
Zhang L; Du Y; Xu S; Jiang Y; Yuan C; Zhou L; Ma X; Bai Y; Lu J; Ma J
Cancer Lett; 2019 Feb; 442():242-251. PubMed ID: 30419349
[TBL] [Abstract][Full Text] [Related]
57. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
58. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
59. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
[TBL] [Abstract][Full Text] [Related]
60. A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells.
Umeh-Garcia M; Simion C; Ho PY; Batra N; Berg AL; Carraway KL; Yu A; Sweeney C
Cancer Res; 2020 Feb; 80(3):418-429. PubMed ID: 31694904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
